SnoRNA-Ribozyme Hybrids: a Novel Strategy for Enhancing and Targeting Ribozyme Activity <b>in Vivo</b>

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		UMA 97-26
IP Type:		Licensable Technology
Title:		SnoRNA-Ribozyme Hybrids: a Novel Strategy for Enhancing and Targeting Ribozyme Activity in Vivo
Inventor:		Maurille J. Fournier
Summary:		A simple and reproducible method of enhancing and targeting ribozyme activity in vivo for the purpose of RNA cleavage.
Tech Type:		Diagnostics/Biomarkers \| Chemical Methods/Libraries and Chemistry and Materials
URL:		http://amherst.cvip-umass.net/index.cfm?fuseaction=tech.index
Contact:		Office of Commercial Ventures and Intellectual Property Phone: 413-545-3606 FAX: 413-545-3632 E-Mail: cvip@research.umass.edu
Organization:		University of Massachusetts at Amherst

Display all intellectual properties for Maurille J. Fournier
Display all intellectual properties for University of Massachusetts at Amherst